Chonnam Med J.
2001 Jun;37(2):177-184.
Clinical Characterization and Prognostic Relevance of CD56 Expression in Patients with Acute Myeloid Leukemia
- Affiliations
-
- 1Department of Internal Medicine, Chonnam National University Medical School, Kwangju, Korea.
- 2Department of Clinical Pathology, Chonnam National University Medical School, Kwangju, Korea.
Abstract
- This study evaluated the clinical characteristics and prognostic relevance of CD56 expression in 145 patients with acute myeloid leukemia (AML). CD56 was expressed in 17.7% of AML cells and 22.8% of the patients with AML had CD56+. There were no significant differences in the clinical and hematological parameters between the CD56+ and CD56-groups. CD56 expression was correlated with CD19 expression. 63.6% of the CD56+ patients were M2 subtype and 78.6% of the patients with t(8;21) had CD56+. The clinical outcomes in patients who received intensive induction chemotherapy did not differ according to the CD56 expression. However, the patients in CD56+ group of AML M2 showed a tendency toward a shorter disease-free survival than those in CD56-group. In conclusion, although this study did not reveal the definitive clinical and prognostic implications of CD56 expression, it was suggest that the CD56+ AML M2 subtype might be associated with reduced disease-free survival.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Chronic Myelogenous Leukemia with Abnormal Expression of N-CAM (CD56) Adhesion Molecule on CD34-negative Non-blastic Myeloid Cells
- Recent advances in the treatment of pediatric acute leukemia
- Treatments for children and adolescents with AML
- Acute Myeloid Leukemia with Intracardiac Thrombus Presenting as Acute Limb Ischemia
- Classification of acute myeloid leukemia
